The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
R. Rosell
Consultant or Advisory Role - Roche (U)
R. Gervais
No relevant relationships to disclose
A. Vergnenegre
No relevant relationships to disclose
B. Massuti
Consultant or Advisory Role - Roche (U)
E. Felip
No relevant relationships to disclose
F. Cardenal
No relevant relationships to disclose
R. Garcia Gomez
No relevant relationships to disclose
C. Pallares
No relevant relationships to disclose
J. M. Sanchez
No relevant relationships to disclose
R. Porta
No relevant relationships to disclose
M. Cobo
No relevant relationships to disclose
M. Di Seri
No relevant relationships to disclose
P. Garrido Lopez
No relevant relationships to disclose
A. Insa
No relevant relationships to disclose
F. De Marinis
No relevant relationships to disclose
R. Corre
No relevant relationships to disclose
M. Carreras
No relevant relationships to disclose
E. Carcereny
No relevant relationships to disclose
M. Taron
No relevant relationships to disclose
L. G. Paz-Ares
Consultant or Advisory Role - Roche (U)
Expert Testimony - Roche (U)